4th Feb 2025 10:41
Indivior PLC - Richmond, Virginia-based maker of medicines to treat substance use disorders - Completes share buyback programme begun in July. Indivior buys back 9.4 million shares at average GBP8.25, worth GBP77.7 million, about USD100.0 million, in total. The buyback was run by Morgan Stanley & Co International PLC. Last week, Indivior promoted David Wheadon to chair, starting immediately. Wheadon joined the Indivior board in June last year. Wheadon is a medical doctor who worked for GlaxoSmithKline, now GSK PLC, and Eli Lilly & Co. Until 2019, he was senior vice president of global regulatory affairs, patient safety & quality assurance at AstraZeneca PLC.
Current stock price: 930.00 pence each, down 1.3% on Tuesday morning in London
12-month change: down 32%
By Tom Waite, Alliance News editor
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.